Alimera makes deal with Emory
Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.
Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.
The agreement gives Alimera the exclusive option to license a unique class of compounds, NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidise inhibitors, as a potential treatment for conditions such as dry age-related macular degeneration (AMD).
Alimera will also receive the exclusive rights to sublicense in ophthalmology and the exclusive rights for non-ophthalmic use. The company will be responsible for the development and commercialization of the compounds and Emory will receive milestone payments and royalties from net sales.
